Keyphrases
Rat Model
100%
Methyl Ester
100%
Treatment-resistant Depression
100%
Anti-depression
100%
Cannabidiolic Acid
100%
MRNA Expression
60%
Antidepressants
60%
Hippocampus
40%
Wistar Rats
40%
Major Depressive Disorder
40%
Medial Prefrontal Cortex (mPFC)
40%
Imipramine
40%
Genetic Model
20%
Serum Levels
20%
Preference Test
20%
Cannabinoid Receptor 1 (CB1R)
20%
Cannabinoids
20%
Forced Swim Test
20%
Immobility
20%
Wistar-Kyoto
20%
Related Conditions
20%
Behavioral Assessment
20%
Behavioral Outcomes
20%
Oral Dose
20%
Locomotion
20%
Oral Administration
20%
Brain-derived Neurotrophic Factor
20%
Corticosterone
20%
Corticosterone Levels
20%
Psychopharmacology
20%
Open Field Test
20%
Oral Ingestion
20%
Saccharin Preference
20%
Cannabidiol
20%
Psychopharmacological
20%
Plasma Corticosterone
20%
Serotonin Transporter
20%
Cause of Disability
20%
Fatty Acid Amide Hydrolase
20%
Behavioral Impact
20%
Corticotropin Releasing Factor Receptor 1 (CRFR1)
20%
Potential Molecular Mechanism
20%
Pharmacology, Toxicology and Pharmaceutical Science
Rat Model
100%
Antidepressant
100%
Treatment Resistant Depression
100%
Wistar Kyoto Rat
66%
Major Depression
66%
Imipramine
66%
Corticosterone
66%
Cannabinoid
33%
Cannabidiol
33%
Brain Derived Neurotrophic Factor
33%
Immobility
33%
Psychopharmacology
33%
Cannabinoid 1 Receptor
33%
Fatty Acid Amidase
33%
Corticotropin Releasing Factor Receptor 1
33%
Serotonin Transporter
33%
Neuroscience
Treatment-Resistant Depression
100%
Methyl Ester
100%
Antidepressant
60%
Hippocampus
40%
Major Depressive Disorder
40%
Corticosterone
40%
Imipramine
40%
Prefrontal Cortex
20%
Brain-Derived Neurotrophic Factor
20%
Locomotion
20%
Cannabidiol
20%
Psychopharmacology
20%
Cannabinoid
20%
Cannabinoid 1 Receptor
20%
Serotonin Transporter
20%
Fatty Acid Amidase
20%
Corticotropin-Releasing Hormone Receptor 1
20%